Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant

Inclusion Criteria: * Males anf Females aged between 18 and 75 * Patients having given their written consent * Patient determined to participate in the test and to respect the requirements * Patient covered by a social insurance * Patient to be kidney transplanted (from a cadaveric donor) * Patient benefiting from the 1st or 2nd kidney transplant * Patient formerly treated by peritoneal dialysis or hemodialysis * Patient receiving a graft with risk of delayed graft function (score\> 7 combining age of the donor, ischemia time, receiver ethnicity and cause of death) * Patient to receive treatment with basiliximab, mycophenolate mofetil, tacrolimus and corticosteroid Exclusion Criteria: * Patient Pregnant or nursing * Patient with a disability that does not ensure the good understanding of the study and its imperatives , or patient having dependency (alcohol, drugs) * Patient receiving doses of epoetin beta or alpha\> 30,000 IU / week or darbepoetin\> 150 microg / week before transplanting * Patient who has participated in a clinical trial in the last month or currently included in another test * Patient in safeguarding justice, guardianship or trusteeship * Patient receiving a third transplant or hyper immune or who have a positive historic cross-match * Patient receiving a preemptive transplant * graft from a living donor * graft with 3 or more arteries * Multi-Organ Transplantation * Patient with heart failure stage\> III * Patients with unstable ischemic heart disease, or have had a major coronary event less than 6 months, stroke or TIA \<6 months or symptomatic arteritis of lower limbs stage ≥ 3 * Patients with active viral infection: hepatitis B, C (PCR + only) or HIV * Patient with a history of anemia from erythroblastopenia * Patient receiving anticoagulant treatment(AVK) before renal transplantation and to be continued after transplant * Patient with a preoperative rate Hb\> 14 g / dL (before ultrafiltration) * A patient with known hypersensitivity to the active substance or to any of the excipients, or to benzoic acid * Patients with poorly controlled hypertension in the weeks before transplantation (Diastolic Blood Pressure ≥ 110 mm Hg with more than 3 antihypertensive drugs)